Background: There is a lack of objective measures of the clinical efficacy of allergen immunotherapy which relies on patients' perception about the effect of this treatment. We studied whether the fraction of exhaled nitric oxide is affected by multiple allergen immunotherapy in polysensitized adult subjects with allergic rhinitis. We also looked for associations between exhaled nitric oxide and subjects' demographics, symptom scores, and pulmonary function tests.Methods: Twenty adult, polysensitized subjects with seasonal and perennial allergic rhinitis who chose to undergo allergen immunotherapy were enrolled. They were evaluated at baseline, and 4, 8, 12, 24, and 52 weeks later. Exhaled nitric oxide was reported as the mean of triplicate determinations.Findings: Our results indicate that multiple allergen immunotherapy did not affect exhaled nitric oxide levels and such levels did not correlate with subjects' demographics and pulmonary function tests. However, exhaled nitric oxide was associated with rhinoconjuctivitis and asthma symptom scores at the end of the study.Conclusions: In polysensitized adult subjects with allergic rhinitis, exhaled nitric oxide levels are unaffected by multiple allergen immunotherapy. © 2013 Columbo et al.; licensee BioMed Central Ltd.
CITATION STYLE
Columbo, M., Wong, B., Panettieri, R. A., & Rohr, A. S. (2013). The effect of multiple allergen immunotherapy on exhaled nitric oxide in adults with allergic rhinitis. Allergy, Asthma and Clinical Immunology, 9(1). https://doi.org/10.1186/1710-1492-9-31
Mendeley helps you to discover research relevant for your work.